Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Roche and Jiangsu Province Bring Down High Cost of Breast Cancer Drug

publication date: Mar 12, 2014
For three years, Roche has been subsidizing the cost of its breast cancer drug Herceptin in parts of China. In Jiangsu province, the company has been donating 8 free vials of the drug for every six vials the province buys at the regular price, effectively creating a 57% discount. Jiangsu province itself now kicks in an additional 67% of the cost, making the drug even more affordable for its cancer patients. As pointed out in a Bloomberg story, the net effect is to reduce a $36,200 cost of treatment down to $5,300. Roche is being generous, but it also has a selfish motive: it hopes to prevent regulators from allowing a China biopharma to produce the drug at a lower cost. More details....

Stock Symbol: (SIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital